|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
However, the response to vemurafenib is limited in BRAF-mutant thyroid cancer.
|
29737325 |
2018 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Knockdown of WIPF1 robustly inhibited anchorage-independent colony formation, migration, and invasion of thyroid cancer cells and suppressed xenograft thyroid cancer tumor growth and vascular invasion, mimicking the effects of BRAF knockdown.
|
27863429 |
2017 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Substantial improvement in the understanding of the oncogenic pathways in thyroid cancer has led to identification of specific molecular alterations, including mutations of BRAF and RET in papillary thyroid cancer, mutation of RAS and rearrangement of PPARG in follicular thyroid cancer, mutation of RET in medullary thyroid cancer, and mutations of TP53 and in the phosphatidylinositol 3'-kinase (PI3K)/AKT1 pathway in anaplastic thyroid cancer.
|
27618325 |
2017 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Correlation of BRAF mutation and SUV<sub>max</sub> levels in thyroid cancer patients incidentally detected in <sup>18</sup>F-fluorodeoxyglucose positron emission tomography.
|
27696232 |
2017 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The BM probe not only enabled sensitive detection of two types of EGFR-associated point mutations located in GC-rich regions, but also successfully identified the BRAF V600E mutation in the serum from a thyroid cancer patient which could not be detected by the conventional sequencing method.
|
28201758 |
2017 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
|
27880942 |
2017 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
To date, role of autophagy during BRAF inhibition in thyroid cancer remains unknown.
|
27754804 |
2017 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We investigated the prevalence and the possible role of TERT promoter, BRAF, and RAS mutations in a series of low-risk well-differentiated follicular-patterned thyroid neoplasms.
|
28975450 |
2017 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study analyzed TERT promoter mutations in various thyroid tumors and examined their relationship with clinicopathologic factors and the BRAF(V600E) mutation in PTC cases.
|
27184112 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Triple combination of PLX4032, SAHA, and TSH is a specific robust regimen to restore RAI avidity in RAI-refractory BRAF V600E-positive thyroid cancer, which warrants clinical trials to confirm.
|
26751190 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thus, TERT with promoter mutations represents a prominent new oncogene in thyroid cancer and the mutations are promising new diagnostic and prognostic genetic markers for thyroid cancer, which, in combination with BRAF V600E mutation or other genetic markers (e.g.
|
26733501 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
RET, BRAF and other protein kinases have been identified as major molecular players in thyroid cancer.
|
27058903 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
By RT-PCR we evaluated the relative levels of 15 microRNAs (miR-221, -222, -146b, -181b, -21, -187, -199b, -144, -192, -200a, -200b, -205, -141, -31, -375) and the presence of BRAF(V600E) mutation and RET-PTC1 translocation in surgically resected lesions from 208 patients from Novosibirsk oblast (Russia) with different types of thyroid neoplasms.
|
26960768 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The CVF approach identified single-mutation driver candidates, such as BRAF V600E in the thyroid cancer dataset.
|
26543077 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
|
26422023 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
As a result of BRAF kinase inhibition, reduction in MEK kinase activity was seen (p < 0.05) in both thyroid cancer cell lines (72 and 75 %, respectively).
|
27179656 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the relationship between the TME and thyroid cancer progression in a mouse model where thyroid-specific expression of oncogenic BRAF and loss of Pten (Braf(V600E)/Pten(-/-)/TPO-Cre) leads to papillary thyroid cancers (PTC) that rapidly progress to poorly differentiated thyroid cancer (PDTC).
|
26818109 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Investigating BRAF((V600E)) inhibitors (BRAFi) as a strategy to treat patients with aggressive thyroid tumors harboring the BRAF((V600E)) mutant currently is in progress, and drug resistance is expected to pose a challenge.
|
26456124 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In addition, persistent/recurrent TC was seen in 8/12 (66.7%) pediatric patients harboring the BRAF(V600E) mutation versus 14/41 (34.1%) patients harboring the wild type BRAF (p = 0.05), and when only conventional papillary TC was examined, in 7/9 (77.8%) cases harboring BRAF(V600E) mutation versus 11/33 (33.3%) cases harboring wild type BRAF (p = 0.025).
|
26711586 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In all cases the detection of BRAF V600E mutation was associated with histopathologically proving the presence of TC (specificity of the test - 100%).
|
26884114 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Matched blood and tissue assays for BRAF(V600E) were performed on 70 patients with PTC (stages I to IV, n = 48) or other (n = 22) thyroid tumors.
|
26631873 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
While the majority of seminomas retain a hypo-methylated genome, a small fraction displays a highly methylated genome, resembling hyper-methylated non-seminomas.It is well established from e.g. melanoma, colorectal and thyroid cancer that a methylated phenotype can be correlated to prognosis and can be related to BRAF mutations.
|
27886677 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Because BRAF and RAS mutations are the most common molecular perturbations associated with well-differentiated thyroid cancer, these findings may assist with improved preoperative risk assessment by suggesting the likely molecular profile of a thyroid cancer, even when postsurgical molecular analysis is unavailable.
|
27689252 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We examined the expression of feedback regulation mechanisms and alterations in the upper signal transduction pathway in thyroid cancer cell lines harboring BRAF mutation.
|
26456083 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |